Related Topics News -

     
 Detail   |   Print    Next page > 
     
《大行》匯豐研究降巨子生物目標價至28.1元 維持「持有」評級
2026-08-21T  
巨子生物跌逾5% 高盛:中期經營利潤遜預期降目標價至33元 維持「買入」評級
2026-08-19T  
《大行》花旗升巨子生物目標價至38.4元 復甦可見度高
2026-08-19T  
《業績》巨子生物中期淨利潤9.4億元人民幣 按年倒退20.5%
2026-08-18T  
《大行》中金下調巨子生物目標價至40元 關注底部佈局機會
2026-06-18T  
巨子生物交聯重組膠原蛋白植入劑獲註冊證
2026-06-17T  
《大行》大摩:內地5月零售總額現疫後首降 消費復甦之路或呈漸進且顛簸
2026-06-17T  
《大行》中金降巨子生物目標價至49元 維持「跑贏行業」評級
2026-03-23T  
《大行》花旗料巨子生物下半年有望復甦 目標價降至37元
2026-03-20T  
《業績》巨子生物全年純利19.15億人民幣跌7.2% 連特別息派121.04分
2026-03-19T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.